
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is viewed favorably because its core revenue engine remains robust, with Jakafi sales of $826.5 million in 3Q26 and underlying demand up about 12% year over year, while Opzelura delivered $254.9 million, up about 36% year over year and supported by stronger prescription demand and new patient starts. The broader ex-Jakafi portfolio also continues to scale, generating about $490 million and rising roughly 37% year over year, which helped management raise FY26 net sales guidance to $5.21 billion to $5.30 billion. Beyond the near-term commercial strength, the company has multiple pipeline catalysts across oncology and dermatology, and its strategic shift toward more attractive programs such as 1L ovarian maintenance and next-generation MPN assets supports longer-term growth despite the eventual Jakafi patent cliff.
Bears say
Incyte is facing a structurally difficult outlook because Jakafi remains the primary revenue source, yet its patent expiry in the 2028 timeframe creates a looming cliff that the current life-cycle strategy may not fully bridge. Its efforts to fragment the myelofibrosis market with combinations and CALR- or JAK2V617F-targeted approaches still carry a high bar, while competitors may have stronger activity across both Type 1 and non-Type 1 patients and could limit future share. Meanwhile, Opzelura may only generate $50-100M per year in milder HS, and the broader pipeline is still uncertain with regulatory risk and possible clinical setbacks in Phase I, II, and III programs.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Incyte (INCY) Forecast
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares